Xontogeny, LLC

CIK 00018442962 companiesNEW YORK, NY

SEC Profile

Transactions

Companies

Filings

CIK

0001844296

Recent Transactions

20 trades

Award
Landos Biopharma, Inc.
Stock Option (Right to Buy)
2021-08-27+10,709→ 10,709 total
Purchase
Landos Biopharma, Inc.
Common Stock
2021-02-09$14.60/sh+34,951→ 7,299,751 total
Purchase
Landos Biopharma, Inc.
Common Stock
2021-02-09$13.80/sh+64,730→ 7,264,800 total
Conversion
Landos Biopharma, Inc.
Series B Preferred Stock
2021-02-08−1,770,600→ 0 total
Purchase
Landos Biopharma, Inc.
Common Stock
2021-02-08$16.00/sh+1,250,000→ 7,049,564 total
Conversion
Landos Biopharma, Inc.
Common Stock
2021-02-08+2,941,769→ 2,941,769 total
Conversion
Landos Biopharma, Inc.
Common Stock
2021-02-08+1,770,600→ 1,770,600 total
Conversion
Landos Biopharma, Inc.
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total
Conversion
Landos Biopharma, Inc.
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total
Conversion
Landos Biopharma, Inc.
Common Stock
2021-02-08+2,857,795→ 5,799,564 total
Conversion
Landos Biopharma, Inc.
Common Stock
2021-02-08+2,857,795→ 5,799,564 total
Purchase
Landos Biopharma, Inc.
Common Stock
2021-02-08$13.10/sh+1,771→ 7,200,070 total
Purchase
Landos Biopharma, Inc.
Common Stock
2021-02-08$11.38/sh+34,611→ 7,111,628 total
Purchase
Landos Biopharma, Inc.
Common Stock
2021-02-08$12.53/sh+86,671→ 7,198,299 total
Conversion
Landos Biopharma, Inc.
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total
Conversion
Landos Biopharma, Inc.
Common Stock
2021-02-08+2,941,769→ 2,941,769 total
Conversion
Landos Biopharma, Inc.
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total
Purchase
Landos Biopharma, Inc.
Common Stock
2021-02-05$11.14/sh+27,453→ 7,077,017 total
Award
Astria Therapeutics, Inc.$ATXS
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+4,851→ 4,851 total
Award
Astria Therapeutics, Inc.$ATXS
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+1,617→ 30,920 total

Companies

Recent Filings

Address

51 ASTOR PLACE, 10TH FLOOR

NEW YORK, NY, 10003

View on SEC.gov